Role of human nucleoside transporters in pancreatic cancer and chemoresistance

作     者：Carly Jade Carter Ahmed H Mekkawy David L Morris 

作者机构：Hepatobiliary and Surgical Oncology UnitDepartment of SurgerySt George HospitalUniversity of New South WalesSydney 2217New South WalesAustralia Mucpharm Pty LtdAustralia 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2021年第27卷第40期

页      面：6844-6860页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：University of New South Wales  UNSW 

主　　题：Pancreatic cancer Gemcitabine Human nucleoside transporters Human equilibrative nucleoside transporters Human concentrative nucleotide transporters Mucins 

摘      要：The prognosis of pancreatic cancer is poor with the overall 5-year survival rate of less than 5%changing minimally over the past decades and future projections predicting it developing into the second leading cause of cancer related mortality within the next *** into the mechanisms of pancreatic cancer development,progression and acquired chemoresistance have been constant for the past few decades,thus resulting in the identification of human nucleoside transporters and factors affecting cytotoxic uptake via said *** review summaries the aberrant expression and role of human nucleoside transports in pancreatic cancer,more specifically human equilibrative nucleoside transporter 1/2(hENT1,hENT2),and human concentrative nucleoside transporter 1/3(hCNT1,hCNT3),while briefly discussing the connection and importance between these nucleoside transporters and mucins that have also been identified as being aberrantly expressed in pancreatic *** review also discusses the incidence,current diagnostic techniques as well as the current therapeutic treatments for pancreatic ***,we address the importance of chemoresistance in nucleoside analogue drugs,in particular,gemcitabine and we discuss prospective therapeutic treatments and strategies for overcoming acquired chemoresistance in pancreatic cancer by the enhancement of human nucleoside transporters as well as the potential targeting of mucins using a combination of mucolytic compounds with cytotoxic agents.